Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • AI and healthcare
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
      • Top Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • AI and healthcare
    • Industry Perspective
  • Home
  • Dermatology
  • Dermatology News
  • Ruxolitinib Cream...

Ruxolitinib Cream Maintains Atopic Dermatitis Control in Children Over 52 Weeks: Phase 3 TRuE-AD3 Trial

Written By : Medha Baranwal ,Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2026-11-20T20:30:36+05:30  |  Updated On 20 Nov 2026 8:30 PM IST
Ruxolitinib Cream Maintains Atopic Dermatitis Control in Children Over 52 Weeks: Phase 3 TRuE-AD3 Trial
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: Ruxolitinib cream demonstrated sustained disease control and a favourable safety profile over 52 weeks in children aged 2 to 11 years with mild-to-moderate atopic dermatitis (AD), findings from the Phase 3 TRuE-AD3 study. The results suggest that as-needed application of the topical Janus kinase (JAK) inhibitor may help maintain symptom control in children requiring long-term management of the inflammatory skin condition.

The findings were published in the Journal of the American Academy of Dermatology by Amy S. Paller, MD, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, and colleagues.
Atopic dermatitis is a chronic inflammatory skin disorder characterized by itching, dryness, and recurrent eczema flare-ups. Managing the condition in children often requires long-term treatment to control symptoms while minimizing treatment-related adverse effects.
Ruxolitinib cream
selectively inhibits JAK1 and JAK2, which are involved in inflammatory signalling pathways contributing to AD.
The initial phase 3 study demonstrated the efficacy and safety of ruxolitinib cream compared with vehicle over eight weeks. The subsequent long-term safety extension evaluated whether disease control could be maintained with intermittent, as-needed application over an additional 44 weeks.
Children aged 2 to 11 years with mild-to-moderate AD who had initially received ruxolitinib cream 0.75% or 1.5% continued using their assigned formulation twice daily as needed. Participants previously treated with vehicle were randomly reassigned to either strength of ruxolitinib cream. Researchers assessed long-term safety and disease control through Week 52.
The analysis revealed the following findings:
  • Safety outcomes: Among 282 children receiving ruxolitinib cream during the long-term extension, no new safety concerns emerged. Application-site reactions were reported in 1.1% of participants.
  • Treatment-related adverse events: No serious adverse events considered related to treatment were observed during the extension period.
  • Disease control: Children initially assigned to ruxolitinib cream 0.75% and 1.5% maintained disease control through Week 52, with Investigator’s Global Assessment scores of 0 or 1 reported in 79.5% and 72.3% of patients, respectively.
  • Affected skin area: The mean affected body surface area remained low at 2.0% with the 0.75% formulation and 1.9% with the 1.5% formulation, indicating sustained control of skin involvement.
The researchers acknowledged that the long-term extension did not include a vehicle control group, limiting direct comparisons with untreated or vehicle-treated patients during this period.
The investigators concluded that as-needed ruxolitinib cream was well tolerated and maintained disease control over 44 weeks of extended treatment in children aged 2 to 11 years. The findings were consistent with previously reported results in adolescents and adults, supporting its potential role in long-term topical management of paediatric atopic dermatitis.
Reference:
Paller, A. S., Stein Gold, L. F., Simpson, E. L., Zaenglein, A. L., Armstrong, A. W., Tollefson, M. M., Soong, W., Lee, L. W., Devani, A. R., Forman, S. B., Siri, D. D., Kallender, H., Angel, B., Li, Q., Purohit, V. S., & Eichenfield, L. F. (2026). 52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.10.072


Journal of the American Academy of DermatologyRuxolitinib CreamAtopic Dermatitis
Source : Journal of the American Academy of Dermatology

Medical Survey

Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Print Article
    Show Full Article
    Next Story
    Recommended For You
    NO DATA FOUND

    Editorial

    Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

    Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev Joshi

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev...

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination - Dr. Makarand Damle

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination...

    Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

    Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

    View All

    Journal Club Today

    Newer Generations Have Better Memory and Experience Slower Cognitive Decline, Study Finds

    Newer Generations Have Better Memory and Experience Slower Cognitive Decline, Study Finds

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok